EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation

Pável Olivera iD, César Velásquez-Escandón, Desirée Campoy, Katia Flores, Tania Canals, Erik Johansson, María José Herranz, Laia Martínez, Juan José Cerezo-Manchado, Ramón Salinas

Clinical and Applied Thrombosis/Hemostasis · 2023

DOI: 10.1177/10760296231180865 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2023. Verfasst von Pável Olivera und 9 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Hemostasis Unit, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain. Hauptthemen laut MEDLINE: Atrial Fibrillation, COVID-19, Stroke. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daiichi Sankyo Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

During the first wave of the SARS-CoV-2 pandemic, management of anticoagulation therapy in hospitalized patients with atrial fibrillation (AF) was simplified to low-molecular-weight heparin (LMWH) followed by oral anticoagulation, mainly owing to the risk of drug–drug interactions. However, not all oral anticoagulants carry the same risk.

Methods

Observational, retrospective, and multicenter study that consecutively included hospitalized patients with AF anticoagulated with LMWH followed by oral anticoagulation or edoxaban concomitantly with empirical COVID-19 therapy. Time-to-event (mortality, total bleeds, and admissions to ICU) curves, using an unadjusted Kaplan-Meier method and Cox regression model adjusted for potential confounders were constructed.

Results

A total of 232 patients were included (80.3 ± 7.7 years, 50.0% men, CHA 2 DS 2 -VASc 4.1 ± 1.4; HAS-BLED 2.6 ± 1.0). During hospitalization, patients were taking azithromycin (98.7%), hydroxychloroquine (89.7%), and ritonavir/lopinavir (81.5%). The mean length of hospital stay was 14.6 ± 7.2 days, and total follow-up was 31.6 ± 13.4 days; 12.9% of patients required admission to ICU, 18.5% died, and 9.9% had a bleeding complication (34.8% major bleeding). Length of hospital stay was longer in patients taking LMWH (16.0 ± 7.7 vs 13.3 ± 6.5 days; P = .005), but mortality and total bleeds were similar in patients treated with edoxaban and those treated with LMWH followed by oral anticoagulation.

Conclusions

Mortality rates, arterial and venous thromboembolic complications, and bleeds did not significantly differ between AF patients receiving anticoagulation therapy with edoxaban or LMWH followed by oral anticoagulation. However, the duration of hospitalization was significantly lower with edoxaban. Edoxaban had a similar therapeutic profile to LMWH followed by oral anticoagulation and may provide additional benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCOVID-19StrokeMaleHumansFemaleHeparin, Low-Molecular-WeightRetrospective StudiesSARS-CoV-2AnticoagulantsHemorrhageHeparinPyridinesThiazoles

Stichwörter der Autor:innen

COVID-19atrial fibrillationedoxabanlow-molecular-weight heparin

Substanzen

Heparin, Low-Molecular-WeightAnticoagulantsHeparinedoxabanPyridinesThiazoles

Autor:innen und Institutionen

  • Thrombosis and Hemostasis Unit, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Department of Hematology, Fundación Sanitària Mollet, Barcelona, Spain.
  • Department of Hematology, General University Hospital of Catalonia, Barcelona, Spain.
  • Department of Hematology, University Hospital Sant Joan de Reus, Tarragona, Spain.
  • Department of Hematology, Hospital Sant Pau I Santa Tecla, Tarragona, Spain.
  • Department of Hematology, University Hospital Clínico Santa Lucía, Cartagena, Spain.

ORCID-Profile: Pável Olivera

Förderung

  • Daiichi Sankyo Company

Zitieren

APA

Olivera, P., Velásquez-Escandón, C., Campoy, D., Flores, K., Canals, T., Johansson, E., Herranz, M. J., Martínez, L., Cerezo-Manchado, J. J., & Salinas, R. (2023). Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296231180865

Vancouver

Olivera P, Velásquez-Escandón C, Campoy D, Flores K, Canals T, Johansson E, et al. Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis. 2023. doi:10.1177/10760296231180865

BibTeX
@article{Olivera2023,
  author = {Olivera, Pável and Velásquez-Escandón, César and Campoy, Desirée and Flores, Katia and Canals, Tania and Johansson, Erik and Herranz, María José and Martínez, Laia and Cerezo-Manchado, Juan José and Salinas, Ramón},
  title = {Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2023},
  doi = {10.1177/10760296231180865}
}
Kostenlos starten →